IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/309% above fair value
$0.18−0.01 (-4.61%)
Close on Nov 13, 2026Market cap $18.20MP/E –Yield –
IGC Pharma total assets
Total assets on the balance sheet at the end of each period.
IGC Pharma's total assets was $9.73M at Sep 30, 2026. For fiscal 2026 it was $9.19M, up 5.0% from the year before. Over ten years it grew -6.9% a year on average. The highest annual figure on record is $35.87M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $9.19M | +5.0% |
| FY2025 | Mar 31, 2025 | $8.75M | -11.7% |
| FY2024 | Mar 31, 2024 | $9.90M | -42.4% |
| FY2023 | Mar 31, 2023 | $17.18M | -36.0% |
| FY2022 | Mar 31, 2022 | $26.83M | -25.2% |
| FY2021 | Mar 31, 2021 | $35.87M | +23.7% |
| FY2020 | Mar 31, 2020 | $28.98M | -15.9% |
| FY2019 | Mar 31, 2019 | $34.47M | +217.6% |
| FY2018 | Mar 31, 2018 | $10.85M | -3.8% |
| FY2017 | Mar 31, 2017 | $11.28M | -40.2% |
| FY2016 | Mar 31, 2016 | $18.86M | -7.2% |
| FY2015 | Mar 31, 2015 | $20.33M | +14.6% |
| FY2014 | Mar 31, 2014 | $17.73M | -7.9% |
| FY2013 | Mar 31, 2013 | $19.25M | -23.8% |
| FY2012 | Mar 31, 2012 | $25.26M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2027CQ4 2025 | Sep 30, 2026 | $9.73M | -0.1% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $9.50M | +19.6% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $9.19M | +5.0% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $9.71M | +7.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $9.74M | -6.0% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $7.94M | -25.0% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $8.75M | -11.7% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $9.08M | -19.4% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $10.37M | -37.2% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $10.59M | -32.4% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $9.90M | -42.4% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $11.26M | -43.9% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $16.51M | -24.8% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $15.67M | -35.1% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $17.18M | -36.0% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $20.07M | -35.9% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $21.96M | -35.1% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $24.17M | -29.8% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $26.83M | -25.2% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $31.29M | +29.5% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $33.84M | +28.4% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $34.44M | +21.7% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $35.87M | +23.7% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $24.16M | -22.3% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $26.35M | -19.9% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $28.30M | -15.5% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $28.98M | -15.9% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $31.10M | -16.3% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $32.89M | +98.7% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $33.51M | +190.9% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $34.47M | +217.6% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $37.16M | +227.8% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $16.55M | +65.6% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $11.52M | +22.0% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $10.85M | -3.8% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $11.34M | +1.5% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $9.99M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $9.44M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $11.28M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $11.17M | – |
See a number that looks wrong?